90Y/177Lu-DOTATATE therapy: Survival of the fittest?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 10, 2011, Pages 1785-1787

  Brans, Boudewijn ^a   Mottaghy, Felix M ^a,b   Kessels, Alfons ^b,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LUTETIUM 177; YTTRIUM 90; 90Y OCTREOTATE, DOTA(0) TYR(3) THR(8); 90Y-OCTREOTATE, DOTA(0)-TYR(3)-THR(8)-; DRUG DERIVATIVE; LUTETIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOISOTOPE;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; HUMAN; NEOPLASM; RADIATION DOSE; RANDOMIZATION; REVIEW; FEMALE; MALE; METHODOLOGY; NEUROENDOCRINE TUMOR; NOTE; RADIOTHERAPY;

FEMALE; HUMANS; LUTETIUM; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; RADIOTHERAPY;

EID: 80455173997     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1878-x     Document Type: Review

References (5)

1. Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with (90) Y-DOTATATE and tandem (90) Y/(177) Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1833-x
2. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with betaemitting radionuclides. J Nucl Med. 1995;36(10):1902-9.
3. Higgins JPT, Altman DG. Assessing risk of bias in included study. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions: The Cochrane Library; 2008.
4. Simon R, Wittes RE. Methodologic guidelines for reports of clinical trials. Cancer Treat Rep. 1985;69(1):1-3. (Pubitemid 15197067)
5. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclidetherapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging. 2010;54(1):92-9.